A Prospective Study of Multi-Target Therapy on Refractory Lupus Nephritis

BAO Hao,ZHANC Haitao,ZHANC Xin,HU Weixin,XIE Honglang,CHEN Huiping,ZENG Caihong,LIU Zhihong,LI Leishi

DOI: https://doi.org/10.3969/j.issn.1006-298x.2007.01.003

2007-01-01

Abstract:Objective:To assess the efficacy and safety of tacrolimus(FK506) combined with mycophenolate mofetil(MMF) and steroid in the treatment of refractory lupus nephritis(LN).Methodology:Ninety-two cases of biopsy proved LN,including class Ⅳ,Ⅳ+Ⅴ,Ⅲ+Ⅴ or Ⅴ(according to ISN/RPS 2003 classification criteria) were randomly assigned to either multi-target therapy group [n=62,induction therapy was FK506(3-4 mg/d) and MMF(0.75-1.0 g/d),then maintained with FK506(1.5-2 mg/d) and MMF(0.5-0.75 g/d)] or CTX-Aza group(n=30,IVC 0.5-1.0 g/m2BSA monthly for 6-9 months,then Aza 1-2 mg/kg·d).All patients received methylprednisolone(MP) pulse therapy at beginning and followed with oral prednisone(0.6 mg/kg·d).The total course of both regimens was 18 months and induction therapy less than 9 months.The primary end point was complete remission(CR) during induction therapy(defined as a value of proteinuria 0.4g/24h with normal urinary sediment,serum albumin ≥35 g/L and a normal value of serum creatinine or no more than 15% above the base-line values).Results:(1)There was no statistics difference in complete remission rate of class Ⅳ LN between multi-target therapy group and CTX-Aza group during induction therapy(75.0% vs 60.0%,P0.05).(2) The complete remission rate of class Ⅳ+Ⅴ LN in multi-target therapy group was significantly higher than that of CTX-Aza group during induction therapy(75.0% vs 16.7%,P0.05).The proportion of patients without proteinuria on the ninth month was also higher in multi-target therapy group.(3) The CR rates of class Ⅳ,Ⅳ+Ⅴ and Ⅲ+Ⅴ LN in multi-target therapy group during induction therapy were 75.0%,75.0% and 66.7%.Yet for class Ⅴcases,it was only 16.7%,notably much lower than that of class Ⅳ and Ⅳ+Ⅴ(P0.05).(4) The CR rates of class Ⅳ+Ⅴ LN in multi-target therapy group,class Ⅳ and Ⅳ+Ⅴ LN in CTX-Aza group improved after the prolongation of induction period to 9 months.(5) 24 patients in multi-target therapy group accepted repeat biopsy after induction therapy.The results showed that the average AI decreased from 9.0±4.0 to 2.1±1.7(P0.01),the proportion of patients with AI≥8' decreased from 75% to 4.2%(P0.01),the average CI increased from 0.7±1.0 to 2.2±1.3(P0.01),and the proportion of patients with CI≥3' increased from 12.5% to 37.5%(P0.05).(6) The adverse effects of upper respiratory infection,gastrointestinal symptoms and leucopenia in the multi-target therapy group were significantly less than that in the CTX-Aza group(P0.05).The temporary GPT/GOT rise,infection and alopecia rates were also lower than that in the CTX-Aza group but with no statistics significance.In contrast,the incidence of new-onset hypertension was higher in the multi-target therapy group(17.74% vs 0%,P0.05).Conclusion:Multi-target therapy with FK506,MMF and steroid was an effective induction therapy with mild adverse effects for class Ⅳ,Ⅳ+Ⅴ and Ⅲ+Ⅴ LN.